Sales of Novo Nordisk’s (NVO) Wegovy and Eli Lilly’s (LLY) Mounjaro doubled in India in July compared to June, Rishika Sadam and Kashish Tandon of Reuters reports, citing research firm Pharmarack. Demand for anti-obesity drugs has been on an upswing in the country.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Cautious Hold Rating on Novo Nordisk Amid Profit Warning and Legal Challenges
- Novo Nordisk Reports Strong H1 2025 Performance
- Novo Nordisk’s Mixed Earnings Call Highlights Growth and Challenges
- Novo Nordisk Shares Down 44% YTD as Wegovy Sales Jump 67%, But Guidance Stays Lower
- Eli Lilly Stock (LLY) Is Dragged Down by Rival Novo Nordisk’s Poor Financial Results